

# INFLAMMATORY BOWEL DISEASE PRESCRIPTION ORDER FORM

PATIENT INFORMATION		PRESCRIBER INFORMATION	
Patient Name: _____		Prescriber Name: _____	
Date of Birth: _____	Gender: M / F	DEA: _____	NPI: _____
SSN: _____		Address: _____	
Address: _____		City, State, ZIP Code: _____	
City, State, ZIP Code: _____		Phone: _____	Fax: _____
Phone: _____		Contact Person: _____	

Today's Date: \_\_\_\_\_

Need By Date: \_\_\_\_\_

**Ship To:**

Patient

\_\_\_\_\_

CLINICAL INFORMATION / ICD-10 CODE	
<b>Patient Diagnosis</b> Primary ICD-10 Code: _____ Rationale for therapy: _____ Current Weight _____ kg/lbs    Height _____ in/cm    BSA _____ m <sup>2</sup> <input type="checkbox"/> NKDA <input type="checkbox"/> Known Drug Allergies _____	<b>List of Current/Periously Prescribed Medications:</b> 1. _____ 4. _____ 2. _____ 5. _____ 3. _____ 6. _____

MEDICATION	STRENGTH	DIRECTIONS	QTY / REFILLS
<input type="checkbox"/> <b>Cimzia</b> (certolizumab pegol)	<input type="checkbox"/> 200mg prefilled syringe <input type="checkbox"/> 200mg lyophilized power vial (healthcare provider administration only)	<b>Initial dose:</b> <input type="checkbox"/> 400mg (given as two 200mg subcutaneous injections) at weeks 0, 2 and 4 <input type="checkbox"/> Other: _____ <b>Maintenance dose:</b> <input type="checkbox"/> 400mg subcutaneous injection every 4 weeks <input type="checkbox"/> Other: _____	<b>Dispense:</b> <input type="checkbox"/> 1 month supply <input type="checkbox"/> 3 months supply Other: _____ Refills: _____
<input type="checkbox"/> <b>Humira</b> (adalimumab)	<input type="checkbox"/> 40mg/0.8mL prefilled syringe <input type="checkbox"/> 40mg/0.8mL pen <input type="checkbox"/> 20mg/0.4mL prefilled syringe	<b>Initial dose:</b> <input type="checkbox"/> 160mg subcutaneously on day 1, then 80mg on day 15, on day 15, then 40mg every other week (per Humira starter kit) <input type="checkbox"/> Other: _____ <b>Maintenance dose:</b> <input type="checkbox"/> 40mg/ subcutaneous injection every other week <input type="checkbox"/> Other: _____ Additional directions (cyclic, one-time, duration of therapy, etc.) _____	<b>Dispense:</b> <input type="checkbox"/> 1 month supply <input type="checkbox"/> 3 months supply Other: _____ Refills: _____
<input type="checkbox"/> <b>Simponi</b> (golimumab)	<input type="checkbox"/> 100mg prefilled syringe syringe <input type="checkbox"/> 100mg SmartJect auto-injector	<b>Initial dose:</b> <input type="checkbox"/> 200mg (given as two 100mg subcutaneous injection) at week 0 <input type="checkbox"/> 100mg subcutaneous injection at week 2 <b>Maintenance dose:</b> <input type="checkbox"/> 100mg subcutaneous injection every 4 weeks <input type="checkbox"/> Other: _____	<b>Dispense:</b> <input type="checkbox"/> 1 month supply <input type="checkbox"/> 3 months supply Other: _____ Refills: _____

PRESCRIPTION INSURANCE INFORMATION	PATIENT BILLING INFORMATION
Insurance Plan Type: _____ Rx BIN: _____	Credit Card: Visa, Mastercard, American Express, Other
Processor Control No. or PCN (if available): _____	Credit Card Number: _____
Identification Number: _____	CVV (last 3-digits): _____
Rx Group: _____	Expiration Date (mm/yy): _____

CURRENT PHARMACY INFORMATION *to be contacted if we have any issues when billing insurance
Pharmacy Name: _____
Pharmacy Phone Number: _____
Pharmacy Fax Number: _____

By signing below, the prescriber gives consent to both, the prescription(s) above, as well as to Newport Lido Pharmacy to act as the prescriber's agent to begin and execute the prior authorization process and to help the patient apply to co-pay assistance programs, including all foundations and manufacturer assistance programs if necessary.

**Do Not Substitute**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

	<h2 style="margin: 0;">Newport Lido Pharmacy</h2> <p style="margin: 0;">351 Hospital Road, Newport Beach, CA 92663</p>	<p style="margin: 0;"><b>Phone: 949-764-6580</b></p> <p style="margin: 0;"><b>Fax: 949-764-6581</b></p>
--	--	---

**IMPORTANT NOTICE:** This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it's received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and phone number set forth herein and obtain instructions as to disposal of the material. In no event should material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. 20160701